{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"condition":["Cáncer colorectal avanzado","Colorectal cancer","Advanced Colorectal Cancer"],"disease":["Cáncer Colorectal Avanzado","Colorectal Cancer","Advanced Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2536604"],"location":["Canada","Belgium","United States","Spain"],"study_start_month":["12"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study of PM60184 in patients with advanced colon-rectal cancer after standard treatment.","description":"Primary objectives: To evaluate the efficacy of PM060184 in terms ofprogression-free survival at 12 weeks (PFS3) in patients withadvanced colorectal carcinoma (CRC) after standard therapy.\nPrimary endpoints: PFS3, defined as the percentage of patients remaining aliveand progression-free at Week 12 (Month 3) after the firsttreatment dose.","dates":{"creation":"2017-12-15"},"accession":"2536604","cross_references":{"EU Clinical Trials Register":["2017-000257-39"]}}